234 related articles for article (PubMed ID: 17848842)
1. Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy.
Lee P; van der Wall H; Seibel MJ
J Endocrinol Invest; 2007; 30(7):590-7. PubMed ID: 17848842
[TBL] [Abstract][Full Text] [Related]
2. Insufficiency fracture of the femoral neck during osteoporosis treatment: a case report.
Iwamoto J; Takeda T
J Orthop Sci; 2002; 7(6):707-12. PubMed ID: 12486478
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score>-2.5 for alendronate therapy: a modeling study.
Schousboe JT; Ensrud KE; Nyman JA; Kane RL; Melton LJ
J Clin Densitom; 2006; 9(2):133-43. PubMed ID: 16785071
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
Tan W; Sun J; Zhou L; Li Y; Wu X
J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
[TBL] [Abstract][Full Text] [Related]
5. [Should bisphosphonate treatment be used for super-old patients with osteoporosis?].
Harada A; Yamamoto S; Kurato S; Iwase T; Inoue K; Sasaki Y; Tanaka T; Fujita M; Nakano T; Ando F
Nihon Ronen Igakkai Zasshi; 2006 Jul; 43(4):459-61. PubMed ID: 16937933
[No Abstract] [Full Text] [Related]
6. Osteoporotic fractures and vitamin D deficiency.
Wong P; Anpalahan M
Aust Fam Physician; 2006 Jul; 35(7):519-20, 522. PubMed ID: 16820826
[TBL] [Abstract][Full Text] [Related]
7. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy.
Gomberg SJ; Wustrack RL; Napoli N; Arnaud CD; Black DM
J Clin Endocrinol Metab; 2011 Jun; 96(6):1627-32. PubMed ID: 21430030
[TBL] [Abstract][Full Text] [Related]
8. Bone mineral density thresholds for pharmacological intervention to prevent fractures.
Siris ES; Chen YT; Abbott TA; Barrett-Connor E; Miller PD; Wehren LE; Berger ML
Arch Intern Med; 2004 May; 164(10):1108-12. PubMed ID: 15159268
[TBL] [Abstract][Full Text] [Related]
9. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
10. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?
Kwek EB; Goh SK; Koh JS; Png MA; Howe TS
Injury; 2008 Feb; 39(2):224-31. PubMed ID: 18222447
[TBL] [Abstract][Full Text] [Related]
11. Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis.
Chiu WY; Lee JJ; Tsai KS
J Clin Endocrinol Metab; 2013 Apr; 98(4):E723-6. PubMed ID: 23471975
[TBL] [Abstract][Full Text] [Related]
12. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Recker RR; Kendler D; Recknor CP; Rooney TW; Lewiecki EM; Utian WH; Cauley JA; Lorraine J; Qu Y; Kulkarni PM; Gaich CL; Wong M; Plouffe L; Stock JL
Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297
[TBL] [Abstract][Full Text] [Related]
14. Clinical results of alendronate monotherapy and combined therapy with menatetrenone (VitK₂) in postmenopausal RA patients.
Suzuki K; Tsuji S; Fukushima Y; Nakase T; Hamada M; Tomita T; Yoshikawa H
Mod Rheumatol; 2013 May; 23(3):450-5. PubMed ID: 22692649
[TBL] [Abstract][Full Text] [Related]
15. Renal function and bisphosphonate safety.
Ott SM; Drueke T; Elder G; Fukagawa M; Jorgetti V; Langman CB; Moe S; McCann L; Wang AY; Weisinger J; Wheeler D
J Bone Miner Res; 2008 Mar; 23(3):453-4; author reply 455. PubMed ID: 17967135
[No Abstract] [Full Text] [Related]
16. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
[TBL] [Abstract][Full Text] [Related]
17. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
Cosman F; Miller PD; Williams GC; Hattersley G; Hu MY; Valter I; Fitzpatrick LA; Riis BJ; Christiansen C; Bilezikian JP; Black D
Mayo Clin Proc; 2017 Feb; 92(2):200-210. PubMed ID: 28160873
[TBL] [Abstract][Full Text] [Related]
18. [Diphosphonates: and alternative to estrogen therapy in postmenopausal osteoporosis. Experience with alendronate].
Buffo L; Rossini M; Buoncristiano A; Girardello S; Zamberlan N; Diani F; Adami S
Minerva Ginecol; 1996 Jun; 48(6):263-72. PubMed ID: 8927288
[TBL] [Abstract][Full Text] [Related]
19. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
Adachi JD
Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
[TBL] [Abstract][Full Text] [Related]
20. [Osteoporotic fracture in menopausal women: alendronate reduces the risk].
Bize R; Lamy O; Peytremann-Bridevaux I
Rev Med Suisse; 2008 Dec; 4(183):2703. PubMed ID: 19157286
[No Abstract] [Full Text] [Related]
[Next] [New Search]
